Related Experiment Videos
Familial lipoprotein disorders and premature coronary artery disease
1Department of Medicine, United States Department of Agriculture Human Nutrition Research Center, Tufts University School of Medicine, Boston, Massachusetts.
Insights
Familial lipid disorders lack clear definitions and treatment guidelines. While niacin shows promise for treating lipoprotein(a) excess, more research is needed for other lipid disorders to reduce cardiovascular disease risk.
Area of Science:
- Cardiovascular Medicine
- Genetics
- Metabolic Disorders
Background:
- Familial lipid disorders, including lipoprotein(a) excess and familial hypercholesterolemia, are heritable and linked to premature coronary heart disease (CHD).
- Current definitions and treatment guidelines for these common familial lipid disorders are lacking.
- Therapy for elevated LDL cholesterol in familial lipid disorders is often underimplemented, even in the United States.
Purpose of the Study:
- To review the current understanding of familial lipid disorders and their association with premature cardiovascular disease.
- To identify gaps in definitions and treatment guidelines for conditions like lipoprotein(a) excess and familial hypercholesterolemia.
- To evaluate the evidence for therapeutic interventions in specific familial lipid disorders.
Main Methods:
- Literature review of studies on familial lipid disorders, lipoprotein(a), HDL deficiency, and LDL cholesterol management.
- Analysis of existing data on the efficacy of treatments like niacin and gemfibrozil in CHD patients with specific lipid profiles.
- Assessment of the need for prospective studies to establish CHD risk reduction benefits.
Main Results:
- Niacin treatment is supported for CHD patients with lipoprotein(a) excess, as it lowers lipoprotein(a) and CHD risk.
- Prospective studies are required to confirm the benefits of CHD risk reduction for lipoprotein(a) excess and HDL deficiency.
- Optimizing lipid profiles and achieving LDL cholesterol levels below 100 mg/dL is recommended for CHD patients with low HDL cholesterol.
Conclusions:
- Clear definitions and treatment guidelines for familial lipid disorders are urgently needed.
- Niacin is a justified treatment for CHD patients with lipoprotein(a) excess.
- Further research, including prospective studies, is essential to guide the management of other familial lipid disorders and reduce cardiovascular risk.
Abstract:
Although there is consensus that lipid variables, especially lipoprotein(a), are heritable and that elevated LDL cholesterol levels should be treated, there are no clear definitions of the common familial lipid disorders associated with premature CHD (lipoprotein(a) excess, FCH, familial dyslipidemia, familial hypoalphalipoproteinemia, familial hypercholesterolemia), nor do we have clear guidelines for the treatment of most of these disorders. Implementation of therapy for elevated LDL cholesterol in familial lipid disorders often has not occurred even in the United States. Before recommendations can be made for subjects with lipoprotein(a) excess and HDL deficiency (who often have combined hyperlipidemia or hypertriglyceridemia), prospective studies documenting benefit of CHD risk reduction must be carried out in subjects with lipoprotein(a) excess and HDL deficiency. One such study is being carried out with gemfibrozil in CHD patients with HDL deficiency. Current data do justify treatment of CHD patients with lipoprotein(a) excess with niacin because niacin has been shown to lower lipoprotein(a) levels as well as lower CHD risk mortality in random CHD patients. With regard to CHD patients with or without HDL cholesterol levels less than 35 mg/dL (0.9 mmol/L), efforts should be made to optimize their lipid profile and reduce their LDL cholesterol levels to less than 100 mg/dL (2.6 mmol/L).